Yes, blame the messenger & not the message. Andre is not doing anything but providing the information since most of you can't access it on your own.
The more information you have then the better you can understand why ATRS trades for $2.05. I provided some info & I also stated on another thread that I thought TEVA/ATRS would get an AB rating.
The Cowen analyst is just giving his opinion. He doesn't know anything more then any of us & probably hasn't even read the FDA's response to the Citizens Petition. I personally think they get an AB rating but my opinion is worth as much as your paying for it.
That doesn't work for me. Use this for your search on twitter
dougheuring @dougheuringaria · 2h2 hours ago
Cowen $MYL Downgrade: Appears Mylan To Persist In Making Wealth-Destroying Decisions
You can only write 140 characters but you can capture a picture & post that which allows a lot more then 140. That's why I can't paste it.
will receive an AB rating on epipen. They believe one of the reasons TEVA was pursuing Mylan was they knew no AB rating was coming. Ouch, I can't paste the entire write-up but you can find it on twitter.
MYL has a P/E of 30 & they're about to lose half the epipen market. TEVA has a P/E of 13 & has a 2.2% divy. Mylan could easily fall to 50.
The shorts will hit the stock hard next week.
of Allergens generic division. Mylan will take a big hit monday as investors try to get ahead of TEVA's exit.
I hope you told them they should seek a buyer since you have no faith current management can maximize the value of the pipeline.